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IMMUNOHISTOCHEMISTRY OF INTRACRANIAL ANEURYSMS 
Mark Skirgaudas and Issam A wad. Neurovascular Surgery Program, Section of 
Neurosurgery, Yale University, School of Medicine, New Haven, CT. 
ABSTRACT 
Little is known about the biologic mechanisms associated with the genesis, growth and 
rupture of intracranial saccular aneurysms. It is postulated that the vascular wall pathologic 
response of aneurysmal disease is associated with abnormal angiogenesis factor 
expression. We have examined the expression and distribution of immunoreactivity to 
angiogenesis growth factors (vascular endothelial growth factor and basic fibroblast growth 
factor) and selected vascular wall matrix proteins (fibronectin, type IV collagen, and alpha 
smooth muscle actin) in the walls of human intracranial aneurysms from surgical biopsy or 
autopsy specimens. Double antibody immunohistochemical stains were performed in 
contiguous fixed sections from 3 control circle of Willis arteries, 5 berry aneurysms, 4 
giant aneurysms and one mycotic aneurysm (3 unruptured, 7 ruptured lesions). The 
aneurysmal wall exhibited diffuse disorganized expression of matrix proteins as compared 
to their organization in control vessels. There was strong patchy expression of VEGF 
within the walls of all aneurysms, including marked staining of capillaries and small 
vessels within the thickened walls of giant lesions. The expression of bFGF was more 
diffuse and occurred around the fibrocytes and myocytes within the disrupted media of 9 of 
10 aneurysms. These results confirm the gross architectural molecular disruption in the 
walls of intracranial aneurysms, and illustrate an apparent biologic response involving 
angiogenesis growth factors. Further research should elucidate the time course and 
possible causal relationships of these changes to aneurysm growth and rupture with the aim 
of possible therapeutic manipulation. 
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INTRODUCTION 
Little is known about specific biologic mechanisms associated with the genesis, growth and 
rupture of intracranial saccular aneurysms. Several studies have suggested factors of host 
predisposition including familial clustering and association with inherited vasculopathies 
including fibromuscular dysplasia and polycystic kidney disease.[1-4] Other factors are 
also believed to affect this disease including arterial hypertension, female gender, increased 
age, and cigarette smoking. [5-7] Hemodynamic factors have been invoked in aneurysm 
formation, including asymmetries at the circle of Willis and peculiar branching pattern of 
parent arteries. [8-10] 
Aneurysms of the anterior communicating artery have been associated with unequal size of 
the proximal segments of the anterior cerebral arteries. Hemodynamic stress and flow 
imbalance could cause mechanical damage to the vessel wall. Glass models of aneurysms 
arising at bifurcation points have shown that hemodynamically generated forces could 
contribute to the focal degeneration of the internal elastic membrane.[9], Increased blood 
How is linked with formation of intracranial aneurysms in 10 to 15% of patients affected by 
intracranial arteriovenous malformations. However, in a study of AVM's, 42% of these 
aneurysms did not seem to be related to proximal or feeding vessels of the AVM.[11] This 
suggests that hemodynamic forces alone may not be totally responsible for this association. 
Nevertheless, intracranial arteries are thought to be more prone to aneurysm than their 
extracranial counterparts because of their thinner walls, lower concentration of elastin, and 
position in the poorly supported subarachnoid space. Each of these factors decreases the 
ability of the intracranial artery to resist the formation of an aneurysm. Rat models of 
aneurysms studied by electron microscopy have shown destructive changes in the luminal 
side of the internal elastic lamina. The elastic lamina is replaced by sparsely lined lumps of 
elastic tissue earlier on in aneurysm formation. Later, the lamina becomes atrophied and 
disappears entirely from the aneurysm wall. [11] Smaller numbers of myocytes seen in the 
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media of these aneurysms may illustrate the reduced biosynthesis of elastic tissue in the face 
of disruption of the vascular wall. These observational studies are corroborated by 
numerous morphometric studies which examine the relative distribution of reticular fibers in 
the media. In one study, a lack of reticular fibers in the media was observed in the 
intracranial arteries of patients with unexplained subarachnoid hemorrhage. [12] A network 
of reticular fibres is present in the media of major intracranial arteries. Collagen type 111, a 
structural matrix protein, is a major component of this reticular network. Several histologic- 
studies found morphologic peculiarities of reticular and connective tissue distribution. [5,13J 
Specimens taken from patients with aneurysms showed decreased reticular fibers in areas of 
artery not involved by the aneurysm suggesting that there was a more generalized deficiency 
of the media.[13,141 These studies elicit the fundamental question as to whether defects in 
the vessel wall are congenital or form from some acquired lesion. Although the deficiency 
of reticular fibres in the media was found to be independent of age and atherosclerosis, this 
deficiency alone could not account for the formation of an aneurysm. Other factors such as 
hypertension and cigarette smoking contribute to a multifactorial etiology for aneurysms. 
Atherosclerosis has been studied in its relationship to the formation of extracranial 
aneurysms. [15] Neovascularization of atherosclerotic plaques is correlated with the extent of 
plaque formation. There are several clinical circumstances in which neovascularization of 
the artery wall plays a prominent role. When large caliber blood vessels are denuded of 
their endothelium, adjacent endothelial cells migrate and proliferate to repair the area. In 
atherosclerosis and in the vascularization of adherent thrombi, small newly formed 
microvessels can rupture and thrombose which can to lead to plaque ulceration and further 
disruption of the vessel wall.[16| Damage to the extracellular matrix is caused by the 
leakage of plasma proteins and cytokines. Inflammatory infiltrates, namely macrophages 
and T lymphocytes surround microvessels and contribute to the remodeling of the vessel 
wall. Smooth muscle cells, which form the major cellular component in the atherosclerotic 
intima and media, were found via cell culture to induce a proliferative response on 
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endothelial cells through a VEGF-like soluble factor. [17] Tissue macrophages have been 
shown to infiltrate the aneurysm wall and produce urokinase-type plasminogen activator and 
metalloproteinases. Abdominal aortic aneurysms are associated with proliferation of the 
vasa vasorum which may be lead to their subsequent growth and rupture. Histopathologic 
examination of the vessel wall in abdominal aortic aneurysms shows an almost complete 
absence of elastin in the media, and the presence of inflammatory infiltrates in the outer 
wall.[15] Lectin used as a marker for microvascular endothelial cells showed significant 
neovascularization in the media and periadventitial areas of the vessel wall. These areas of 
neovascularization were populated by macrophages, monocytes, and lymphocytes. 
Discussions based on these findings have indicated that smooth muscle cells damaged by 
ischemia may induce the release of angiogenesis factors that stimulate neovascularization 
and disruption of the artery wall. 
Although silver stains of reticular fibers pointed toward an exploration of the vessel wall 
matrix, a more detailed examination of the proteins and components of the vessel wall has 
been pursued. Several investigators have attempted to identify molecular abnormalities in 
relation to aneurysm pathogenesis.[13,18] Patients with ruptured cerebral aneurysms were 
found to have deficiencies of type III collagen by chromotographic analysis of fibroblasts 
cultured from their tissue. It is interesting to note that other conditions with known collagen 
abnormalities such as Ehlers-Danlos and Marfan syndrome have increased incidence of 
systemic aneurysms but sparing of the cerebral circulation.[19] A relative deficiency of 
Collagen III has been reported in aneurysm walls. [ 13,20) Collagen provides most of the 
major load-bearing capability to the vessel wall. The relative deficiency observed in 
patients with ruptured aneurysms was found not to alter the mechanical strength of the 
vessel wall, but rather result in an increase in the extensibility of the artery. [20] A study of 
cultured fibroblasts from cases of familial cerebral aneurysms failed to demonstrate any 
deficiency as compared to controls. [21] It is unclear how much such a deficiency, alone, 
could account for the formation and rupture of aneurysms. 
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Recent studies have revealed disorganization of basement membrane structural proteins in 
the walls of intracranial aneurysms and in other stressed vascular structures.[22,23] 
Immunofluorescent stains of the aneurysm wall showed that collagen I was found in all 
three layers of the media. Control vessels expressed collagen I only in the adventitia and on 
the basement membrane of endothelial cells. The same haphazard dispersion of fibronectin 
was also observed while control vessels expressed fibronectin limited to the medial layer. 
Observations made by light microscopy confirmed the loss of distinct arterial wall layers. 
Collagen I normally gives support and tensile strength to the vessel wall while fibronectin is 
involved in growth and repair of the vascular wall. This study clearly illustrated the 
dispersion of matrix proteins and loss of structural integrity in the aneurysm wall. Another 
study examined the secretion of proteolytic enzymes by skin fibroblasts from one patient 
with multiple intracranial aneurysms and a family history of aneurysm disease compared to 
secretion by fibroblasts from patients with "sporadic" isolated aneurysms as well as non- 
aneurysmal controls. The familial patients fibroblasts were found to have elevated 
collagenase activity. Endoproteinase secretion was also found to be elevated. Thus, 
enzymatic injury may induce weakness of the arterial wall.[l 1] 
Imbalances of serum protease have been studied previously in patients with abdominal 
aortic aneurysms.[24] Elastase-alpha-1 -antitrypsin ratios have been found to progressively 
increase from the pathophysiologic stages of occlusive aortic disease through subsequent 
aneurysm formation and rupture.[25] Several investigators adopted these assays in the 
investigation of intracranial aneurysms. One study found a trend toward higher elastase- 
alpha 1 antitrypsin serum levels in patients with ruptured aneurysms but not in patients with 
unruptured aneurysms.[26] Another study showed that heterozygosity for alpha 1 
antitrypsin deficiency was 2.5 times more common in patients with intracranial aneurysms 
than in the general population.[27] Elastase and Alpha-1 antitrypsin derangements have 
been documented via genetic and environmental factors. [28] Cigarette smoke induced 
oxidation of the active methionine site in AAT decreases its affinity for elastase more than 
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2000 fold.[29] A recent review article on intracranial aneurysms found that cigarette 
smoking rather than hypertension, gender, or age was the risk factor most consistently 
linked to aneurysm formation. [30] One of the problems with the assessment of serum 
elastase levels lies in its nonspecific nature. Inflammation, trauma, surgical manipulation, 
and infection all raise elastase levels. 
These studies have suggested profound disruptions in the molecular milieu of the aneurysm 
wall which are likely to contribute to lesion genesis and possibly rupture. Yet, specific 
causative mechanisms associated with the biologic behavior of the lesions have remained 
elusive. The expression of factors mediating angiogenesis and vascular permeability in the 
wall of human cerebral aneurysms has not been examined previously. 
In this study, we examine the immunohistochemical expression of a number of 
angiogenesis growth factors and matrix proteins in the wall of human saccular intracranial 
aneurysms. We document gross patterns of immune expression of these probes among 
ruptured and unruptured berry aneurysms, giant saccular aneurysms, and a mycotic 
aneurysm. These are compared to the expression of the same probes in control circle of 
Willis vascular wall from postmortem specimens. The expression and distribution of these 
molecules are interpreted in light of possible mechanisms of vessel damage, repair and 
aneurysm formation and growth. 
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PATIENTS AND METHODS 
Sections of aneurysm or normal vessel wall were obtained at the lime of surgical clipping 
or at autopsy as summarized in Table 1. These included 3 specimens from non-aneurysmal 
control vessels, 2 specimens from unruptured berry aneurysms(<2.5 cm), 3 specimens 
from ruptured berry aneurysms, 4 specimens from giant saccular aneurysms(>2.5 cm), and 
1 specimen from a ruptured mycotic aneurysm. The specimens were fixed in formalin, 
embedded in paraffin blocks and cut into 6 micron thick sections. The tissue was 
deparaffimzed in xylene and prepared for immunohistochemical staining. Contiguous 
sections from each of the specimens were subjected to immunohistologic staining for each 
of the five molecular probes as described below. These probes included antibodies against 
vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and 
vascular wall matrix proteins fibronectin, collagen type IV, and alpha smooth muscle actin. 
For each specimen and each antibody probe a complementary polyclonal or monoclonal 
negative control was also performed. 
Immunostaining for Angiogenesis Growth Factors 
Immunostaimng for VEGF utilized the following procedure. Endogenous peroxidase 
activity was quenched by exposing the slides to 3% hydrogen peroxide in methanol for 30 
minutes. After rinsing with Tris buffered saline for 10 minutes while stirring gently, the 
tissue on the slides was blocked with normal goat serum for 20 minutes. Preimmune rabbit 
IgG or primary anti-VEGF IgG antibody (provided by Dr. Daniel T. Connolly, Ph.D., 
Monsanto Company, St. Fouis, MO), were added to a phosphate buffered saline solution 
of 1% bovine serum albumin and 0.1% Tween 20 detergent at a dilution of 1:800, and 
allowed to incubate at 4°C for 20 hours. The slides were again rinsed in Tris buffered 
saline for 10 minutes. The following steps employed the Vectastain Elite ABC kit and 

Vector DAB ehromogen (Vector Laboratories, Burlingame, California) which were chosen 
for their sensitivity and reliability in our laboratory. A 30 minute incubation with 
biotinylated secondary antibody was followed by a standard 10 minute Tris buffered saline 
rinse. Another 30 minute incubation with the provided avidin/peroxidase complex was 
again followed by a Tris buffered saline rinse, and by incubation with a peroxidase 
substrate solution. Following another wash, the slides were counter stained with 
hematoxylin, for better cytoplasmic visualization, mounted, and examined microscopically. 
All specimens were run in parallel and compared with controls using preimmune rabbit 
serum primary antibody. 
The immunostaining procedure for bFGF was identical to that for VEGF except for using 
normal horse serum was used for the blocking step prior to the incubation (20 hours at 
4°C) with primary anti-bFGF IgG (Oncogene Science, Cambridge, Mass.). Preimmune 
mouse IgG served as the control. 
Immunostaining for Vascular Wall Matrix Proteins 
After deparaffinization and rehydration, the sections immunostained for fibronectin and 
collagen IV underwent digestion for 7 minutes with protease prior to primary incubation 
(the alpha smooth muscle actin specimens required no pretreatment). This was followed by 
a 7 minute tap water rinse and a 20 minute preimmune goat IgG blocking step. The 
primary antibody solutions and incubation times were as follows. A polyclonal antibody to 
fibronectin (Dako, Carpinteria, California) was used at a dilution of 1:2000 in 1% bovine 
serum albumin solution. Sections were incubated for 1 hour at 37°C. A monoclonal 
antibody to collagen type IV (Dako, Carpinteria, California) was used at a 1:25 dilution in 
1% bovine serum albumin. Sections were incubated for 1 hour at 37°C. A monoclonal 
antibody to alpha smooth muscle actin was used at a dilution of 1:50 in 1% bovine serum 
albumin. The following steps utilized Kirkegaard ABC kits (Kirkegaard and Perry 

Laboratories, Inc; Gaithersburg, MD) and Vector Alkaline Phosphatase Substrate kits 
(Vector Laboratories, Burlingame, California). After a 10 minute Tris buffered saline 
rinse, a biotinylated goat anti-mouse IgG was applied for 30 minutes at room temperature. 
A biotinylated goat anti-rabbit IgG was applied for the polyclonal fibronectin. Following 
the secondary antibody incubation step, all sections underwent a 10 minute Tris buffered 
saline rinse, a 30 minute incubation in streptavidin-phosphatase solution, another 10 minute 
Tris buffered saline rinse, and final incubation in Tris buffered solution (pH 8.2) and 
alkaline phosphatase. This last incubation was 8 minutes duration for collagen type IV, 
and 2 minutes duration for fibronectin and smooth muscle actin. Each specimen was run in 
parallel with monoclonal (mouse IgG serum) and polyclonal!rabbit IgG serum) antibody 
controls (Dako, Carpintena, California). The reaction was stopped by rinsing the slides 
with distilled water. Sections were then counter stained with hematoxylin, dehydrated, 
cleared in xylene, and mounted under coverslips. 
The pattern and distribution of immunoexpression of the respective probes were noted in 
each specimen. Staining intensity was recorded as nil (0), faint (1), moderate (2), or 
intense (3). All of the specimens were observed with a neuropathologist. Several runs of 
histochemical assays were performed for each set of antibody probes. After visualization 
of the complete set of specimens, patterns of expression were deduced and tabulated. All 
specimens were included in this assessment. 
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RESULTS 
Angiogenesis Growth Factors 
Results of immunostaining for angiogenic growth factors are summarized in Table 2. 
There was no detected expression of bFGF in non-aneurysmal tissues. There was also no 
expression of VEGF in non-aneurysmal vessels except for limited patches of faint VEGF 
immunostaining in association with atherosclerotic change in circle of Willis vessels from 
two older control patients. 
Staining for bFGF showed a pattern of positive expression in 9 of 10 aneurysm specimens. 
This was noted exclusively within the media, around individual smooth muscle cells (Fig. 
1). Vascular tissue from the unruptured giant aneurysms with fibrosed atrophic media and 
regions of decreased smooth muscle actin expression, also exhibited scantier bFGF 
expression in the same regions. Expression of VEGF occurred in 10 of 10 aneurysm 
vessel walls. This expression occurred in patches affecting all layers throughout the 
aneurysms wall (Fig. 2). Most specimens showed intense staining in the adventitial layers 
and in regions with most profound vessel wall structural disruption (see below). In several 
cases, there was strong VEGF staining surrounding numerous capillaries and other small 
vessels of the adventitia and media of the aneurysm wall (Fig. 3 ). This apparent neovessel 
proliferation with strong VEGF staining was most prominent in the walls of giant 
aneurysms and in the mycotic aneurysm. The presence of angiogenesis factor expression 
within select areas of the vascular matrix contrasted with an absolute lack of expression in 
non-aneurysmal control vessels simplified the assessment of the specimens. Three 
experimental runs using the same set of specimens and protocols revealed identical staining 
patterns in the aneurysmal vessels and no expression in the control vessels. 

14 
Structural Matrix Proteins 
Results of immunostaining for structural matrix proteins are summarized in Table 3. Non- 
aneurysmal specimens taken from the circle of Willis expressed Collagen IV in a regularly 
defined band in the media, and in a distinct subendothelial layer (Fig. 4 ). Fibronectin 
displayed a faint, more diffuse band of expression in the media and adventitia of control 
vessels, and along the subendothelial layer while expression of alpha smooth muscle actin 
in these non-aneurysmal vessels was along a regular and organized medial layer (Fig. 4 ). 
In contrast, the aneurysm vasculature displayed a gross loss of organization of the above 
layers. This was seen on standard hematoxylin and eosin stains and was confirmed by 
observation of individual molecular protein probes by immunocytochemistry. Collagen IV 
staining was faint and diffuse, with loss of well defined bands observed in control arteries 
(Fig. 5). The expression of alpha smooth muscle actin illustrated a decrease in the 
regularity and bulk of the media in the aneurysm vessel walls. In the walls of giant 
aneurysms there were several patches of apparent loss of medial structure, including absent 
alpha smooth muscle actin. In other regions there was diffuse patchy expression within a 
thickened media (Fig. 6). Fibronectin expression was also faint and diffuse in aneurysm 
specimens, except for several instances of more concentrated subendothelial patchy 
expression (Fig. 7). 
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FIGURE 1. Top, negative control. 
Bottom, bFGF immunoexpression around individual myocytes 
within the medial layer of a small unruptured berry aneurysm. 
(40x) 
This dye sublimation print was created 
and/or printed by 
Biomedical Communications 
Yale School of Medicine 
333 Cedar St IE-93 (203) 785-4088 
File# o34?e?o 
FIGURE 2. Top, negative control. 
Bottom, dense patchy expression of VEGF throughout the wall of 
a ruptured berry aneurysm. (1 Ox) 
A=adventitia, M=media 
This dye sublimation print was created 
and/or printed by 
Biomedical Communications 
Yale School of Medicine 
333 Cedar St IE-93 (203) 765-40SS 
File # 2-V<t, PC , 
FIGURE 3. Top, negative control. 
Bottom, positive expression of VEGF around periadventitial capill¬ 
aries, highlighting neovascular invasion of a giant aneurysm. 
This was most prominent in thick fibrotic regions of the aneurysm 
wall. (1 Ox) (Arrows point to capillaries) 

FIGURE 4. Positive immunostaining of collagen Type IV (Top), 
fibronectin (middle), and smooth muscle actin (bottom) in control 
circle of Willis arteries. Note the well defined bands of immuno- 
expression of the respective structural molecular probes. (4x) 
A=adventitia, M=media, E=endotheiium 
This dye sublimation print was created 
and/or printed by 
Biomedical Communications 
Yale School of Medicine 
333 Cedar St IE-93 (203) 785-4088 
File # 70 33 ^Q ( , 
FIGURE 5. Top, negative control. Middle, positive faint immunostain- 
ing of collagen Type IV dispersed throughout the wall of an unrup¬ 
tured berry aneurysm. (10x) Bottom, higher magnification of the arterial 
media showing the scattered punctate-appearing expression of 
collagen Type IV without any semblance of organized banding. (40x) 
This dye sublimation print was created 
and/or printed by 
Biomedical Communications 
Yale School of Medicine 
333 Cedar St IE-93 (203) 735-4Odd 
File # Q ^ 103 
FIGURE 6. Top, negative control. 
Bottom, positive immunoexpression of alpha smooth muscle actin 
within the disrupted myocytic medial layer of the wall of a giant 
aneurysm. The positive myocytes appear disoriented and do not 
form any recognizable bands. (40x) 
This dye sublimation print was created 
andlor printed by 
biomedical Communications 
Yale School of Medicine 
333 Cedar St IE-93 (203) 705-4000 
File # 0~?£( '7Q'5U VLO ■ C 
FIGURE 7. Top, negative control. 
Bottom, positive faint expression of fibronectin in the aneurysm 
vessel wall with loss of organized layers. (1 Ox) 
This dye sublimation print was created 
and/or printed by 
Biomedical Communications 
Yale School of Medicine 
333 Cedar St IE-93 (203) 7S5-4O0S 
File # LgO <- ' 
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DISCUSSION 
Aneurysmal degeneration of intracranial arteries is a complex biologic response reflecting 
the interplay of numerous inherited and acquired factors.[5,31,32] The genesis of 
aneurysmal lesions, their growth, and their eventual rupture may be conceptualized as 
phenomenon of arterial wall failure.[33-35] Such failure may be the result of direct 
vascular wall stress or injury, or could represent compromised homeostatic maintenance or 
repair mechanisms.[9,10,36] Numerous structural and molecular abnormalities within 
aneurysmal tissue have been well characterized. None has been shown to play a direct 
causative role in the pathophysiology of these lesions. [14,18,22,37,38] A myriad of other 
questions remain unanswered, including why some aneurysmal lesions never grow or 
rupture, why some lesions rupture at smaller size while others reach giant proportions, and 
why some giant lesions may be associated with pronounced peri-lesional edema. Some 
lesions present at surgery with an extraordinarily thin wall, heralding impending 
disintegration. Other lesions are more fibrotic and thickened. Yet, some aneurysms exhibit 
focal areas of wall thinning and vulnerability to rupture, while the remainder of the sac may 
be fibrous and resilient. A better elucidation of the biologic response accompanying 
aneurysmal wall failure may clarify a number of questions related to pathogenesis, and may 
allow innovative strategies of therapeutic intervention. 
We hypothesized that aneurysmal wall failure may be accompanied by expression of 
angiogenic factors that could either mediate lesion growth or reflect ongoing repair 
mechanisms. We also sought to confirm the extent of architectural structural disruption in 
the aneurysm wall as reflected by the pattern of immunostaining to fibronectin (a key matrix 
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protein linked to angiogenic activity), alpha smooth muscle actin (reflecting the status of 
smooth muscle density and organization in the vascular media), and collagen Type IV (a 
constituent of basement membrane that plays a fundamental role in vessel wall integrity and 
that interacts closely with various factors related to angiogenic activity). 
Angiogenesis Growth Factors 
The processes of new vessel genesis during embryonic development (vasculogenesis) and 
the sprouting of vessels from pre-existing vascular beds during organogenesis and in 
pathologic processes such as inflammation, wound healing and tumor growth 
(angiogenesis) have been studied extensively in recent years.[39-42] Angiogenesis is 
usually a tightly regulated set of events that remains active for short periods of time and is 
then inhibited. However, unregulated secretion of growth factors is responsible for many 
common diseases. In arthritis, small capillaries invade cartilage and the joint space. Ocular 
neovascularization of the retina is the most common cause of blindness in the United 
States. Tissue microvasculature is normally quiescent with endothelial cell turnover 
occurring over a period of years. During angiogenesis of wound healing this process takes 
place in a matter of days. Several factors have been identified which mediate endothelial 
cell and other vascular wall element proliferation, migration and adhesion.[41,43-45] 
These factors include aFGF, bFGF, VEGF/VPF, PD-ECGF, TGF-alpha, Angiogenin, 
TGF-beta, and TNF-alpha. Several of these factors have been shown to affect the integrity 
of the vessel wall matrix, vascular permeability, and the remodeling of vessel wall in 
response to stress or injury. [23,46-49] 
VEGF, initially identified as vascular permeability factor (VPF), possesses unique features 
of endothelial cell target specificity. [41,50] It promotes the permeability of vascular beds, 
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and is thought to play a pivotal role in the initiation of angiogenesis, the recruitment of 
neovessels, and in a number of pathologic processes including peritumoral brain 
edema.[42,51,52] Vascular permeabilty factor is thought to induce cytosolic calcium 
transients and change endothelial cell shape, resulting in the opening of inter-endothelial 
cell junctions in the post capillary venule.[20] Human glioma specimens showing 
vasogenic brain edema and tumor associated cysts were found to stain positive for 
VEGF/PF diffusely in a heterogeneous pericellular interstitial pattern. [53] 
Although a variety of cells can synthesize and secrete VEGF under pathologic conditions, 
including fibrocytes, myocytes and astrocytes, its unique target is the endothelial 
cell. [31,50,54,55] The actions of VEGF are thought to initiate changes favoring leakage at 
intercellular junctions, and the secondary activation of pathways causing enzymatic 
breakdown of matrix proteins.[49,56] VEGF is also thought to initiate a number of tightly 
controlled steps resulting in new capillary tube formation, microvascular sprouting and 
arborization, and subsequent maturation of proliferating vessels. [41,46,57] 
VEGF is expressed during the early phases of atherogenesis, and in a wide variety of 
pathologic processes including inflammation and tumor growth. [46,50,54,58] Abnormal 
hemodynamic stresses are thought to result in the activation of angiogenesis, with VEGF 
mediating subsequent vascular wall response.[33,41] As such, abnormal VEGF 
expression has been shown in the setting of atherosclerotic lesions, and more recently in 
hemodynamically stressed vessels of arteriovenous malformations. [21,59-61] 
We have documented two distinct patterns of expression of VEGF lmmunoreactivity within 
the walls of intracranial aneurysms. The first pattern involved patchy zones of VEGF 
immunoreactivity spanning the whole width of distorted and disorganized vascular walls. 
The second pattern was discretely defined VEGF immunoreactivity highlighting apparent 
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neovessels within the walls of giant aneurysmal lesions. These findings have not been 
described previously, and are consistent with an activated angiogenic response within 
aneurysmal lesions. It is possible that VEGF activity results in enhanced vascular wall 
permeability, which would contribute to vessel wall disintegration and failure. It is also 
possible that this enhanced VEGF activity may mediate peri-aneurysmal edema in giant 
lesions, similar to its mediation of edema around metastases and other intracranial 
tumors.(42,51] Lastly, it is apparent that VEGF may be involved in neovessel recruitment 
accompanying the growth and organization of giant aneurysms. 
Basic fibroblast growth factor (bFGF) is another factor involved in angiogenesis, and it has 
been shown to have a wider spectrum of target cells, including fibrocytes, myocytes, as 
well as endothelial cells. 140,62,63] The induction of myocytes and endothelial cell have 
been shown to involve bFGF in the developing embryo.[62] Neurons and glial cells have 
been shown to differentiate after exposure to fibroblast growth factor. It was originally 
characterized from bovine pituitary as a 146 amino acid protein. Molecules with identical 
properties have been purified from brain, retina, and adrenals. [40,62] Basic fibroblast 
growth factor requires heparin as a cofactor for binding to its receptors. Basic fibroblast 
growth factor has been shown to induce tumor growth and neovascularization in a similar 
manner to VEGF. It is thought to act in a synergistic fashion along with VEGF, mediating 
the proliferative response and subsequent vascular wall maturation during 
angiogenesis. [64] In addition to its wider spectrum of target cell lines, bFGF differs from 
VEGF in that it is thought to be stored within cells or linked to components of the 
extracellular matrix, to be released and activated upon degradation of the matrix or upon cell 
damage or lysis. [62,65] The interaction of bFGF with specific heparan sulfate moieties 
determines its secretion and distribution. Balloon catheter injury of an artery is typically 
followed by proliferation of VSMC with subsequent mtimal thickening. Incubation of 
vascular smooth muscle cells with IL-1 induced nitric oxide release, cytotoxicity and 
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subsequent release of bFGF.[66] This sequestration of bFGF within the extracellular 
matrix explains why these potent growth factors remain mostly inactive.[43] The 
expression of bFGF within the aneurysmal wall exhibited a very different pattern than 
VEGF. Immunostaining appeared to outline individual myocytes within the disorganized 
aneurysmal medial layer, and was correspondingly absent in regions of the vessel wall 
which lacked smooth muscle cells (and alpha smooth muscle actin expression). These 
findings are consistent with a possible role of bFGF in the particular remodeling of the 
medial wall. 
Structural Matrix Proteins 
Several investigators have demonstrated gross angio-architectural disruption within the 
aneurysmal arterial wall, and a loss of distinct cellular and lamellar layers. [12,14,22,67] 
Physical forces such as hemodynamic stress and hypoxia can alter shape and function of 
matrix components. Cyclic stretch has been shown to affect the growth and morphology of 
aortic smooth muscle cells and to release proteases and prostacyclin by hemodynamically 
stressed endothelial cells.[68] Wall tension and shear stress can alter the binding 
interactions between fibronectin, laminin, collagen IV, and their specific receptor regions. 
Each of these molecules has the potential to interact with multiple components of the ECM. 
For example fibronectin type III domain is also found in tenascin, collagens IV, XII, and 
XIV,and integrin beta-4. Changes in the density of fibronectin-coated microbeads have 
been shown to alter growth and viability of endothelial cells in culture. Therefore any 
alteration in cell or component density or shape can alter the structural integrity and ability 
of the vessel wall to maintain homeostasis. The expression and distribution of selected 
vascular wall matrix proteins which we have documented is consistent with such profound 
disruption. 
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The absence of a well defined band of intense collagen type IV expression within the 
aneurysmal wall, and the presence of faint, diffuse and patchy expression of this probe 
throughout the arterial media are consistent with proteolysis of this molecule in association 
with aneurysmal disease. Increased collagenase type IV activity and other 
metalloproteinases within the vascular matrix have been demonstrated in association with 
activated angiogenesis.[49,56,69] It is possible that the activation of the angiogenesis 
cascade within aneurysmal walls results in breakdown of matrix proteins, including 
collagen type IV, and that such breakdown may contribute to aneurysmal wall failure. A 
similar loss of layered and organized expression of fibronectin within aneurysm walls was 
described by Austin, et. al.[22] and was confirmed by our own results. A more diffuse 
availability of fibronectin within the aneurysm wall may create a favorable milieu for 
endothelial cell proliferation and new capillary growth. [70] This may also be linked to the 
angiogenic process. 
The disrupted expression of alpha smooth muscle actin in aneurysm walls illustrates 
another dimension of angio-architectural disorganization. Myocytes within the medial layer 
of aneurysms were no longer oriented within tightly compacted and presumably functional 
bands. Instead, presumed myocytes exhibiting alpha smooth muscle immuno-expression 
had become loosely disoriented within diffuse patchy zones. Such myocytes were lacking 
altogether in certain regions of giant aneurysm walls, and were replaced by a dense l ibrotic 
response lacking alpha smooth muscle expression. The same fibrotic zones were 
prominently invaded by neovessels as described previously. These observations raise 
interesting questions about the loss of muscular resilience in aneurysmal walls, and also 
about the relationship of this process to the angiogenic response. Studies of the internal 
elastic lamina in rat models of aneurysm have shown disappearance of elastic tissue 
correlated with smooth muscle defects in the media. A decrease in the number of myocytes 
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and a disruption of their function would interfere with the biosynthesis of elastic tissue by 
these cells. [11] 
The extracellular matrix not only responds to the actions of soluble growth factors but in 
many instances controls the actions of these substances. Disorganization of the basement 
membrane in the walls of intracranial aneurysms enhances the chaotic angiogenic response 
in diseased tissue. An example of this interaction occurs with the interactions of the ECM 
component, heparan sulfate, and fibroblast growth factors. Binding to heparan sulfate is 
necessary for binding of bFGF to high-affinity receptors that elicit responses within the 
cells. Binding also prevents degradation of bFGF.[68] Matrix components also interact 
with activators of proteolysis to prevent excessive matrix degradation. Disorganization of 
the stable foundation through which the soluble growth factors interact, allows for an ever 
increasing cascade of vessel wall disruption. 
Potential significance and future Directions 
The immunohistochemical mapping of the aneurysm wall for selected molecules allows a 
gross biochemical dissection, but does not demonstrate specific pathophysiologic 
mechanisms. For example, the abnormal expression of a growth factor does not 
necessarily imply upregulation of receptor density nor increased binding, both of which 
would be necessary for enhanced activity of the growth factor. Similarly, disruption of 
expression of a structural molecular probe does not prove specific ongoing enzymatic 
activity. Furthermore, while immunohistochemistry allows the documentation of gross 
intensity of immunoreactivity, it must be recognized that this intensity may vary not only 
with the amount of angiogenic and structural markers present, but also with artifactual 
factors such as location of specimen within the lesion, preparation, slide thickness, 
paraffinization, enzyme digestion, and variability of chromogen staining. |71,72] Several 
studies on fixation artifact in brain tissue have revealed the efficacy of proteolytic 
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pretreatment that was utilized in this study. [71-73] Pretreatment with a protease such as 
pepsin or trypsin gives increased immunoreactivity throughout the tissue. Formalin 
fixation causes protein cross-linking which impairs access of the immunoprobes. 
Proteolysis accomplishes an unmasking of antigens that can then bind to their 
complementary antibody probes. A study of the expression of basement membrane and 
endothelial cell adhesion molecules in vascular malformations of the brain using 
immunofluorescence did not demonstrate a significant advantage over peroxidase staining. 
The study demonstrated expression of differential patterns of expression of laminin, 
fibronectin, and factor 8 related antigen in vascular malformations. Immunofluorescence 
produced several problems with a quenching phenomenon that occurred in the presence of 
strong light sources such as the UV microscope. Deterioration of fluorescence occurs after 
as little as four seconds of exposure under intense light. Once deterioration of signal 
occurs, the expression patterns can not be seen again.[74] Advantages of 
immunocytochemistry with non-fluorescent chromogens include the ability to obtain 
permanent specimens that allow easy visualization with a standard light microscope. There 
is no degradation of staining intensity over time. Additionally, observation under standard 
light microscopy allows better visualization and enhanced detail of the vessel wall. Each 
component (collagen IV, smooth muscle actin, and fibronectin) showed characteristic 
patterns for each set of samples. The results section as well as accompanying figures 
attempted to show representative patterns for each of these factors. In terms of 
angiogenesis factors, the absolute presence of VEGF and bFGF in the wall of the 
aneurysm contrasted with the total lack of VEGF and bFGF in the non-aneurysmal tissue 
as well as consistent patterns of expression (periadventitial expression of VEGF and medial 
expression of bFGF) does not mandate a further quantitative analysis. A summary of 
immunohistochemical expression by each of the probes is explained in the results section. 
This table attempts to quantify the pattern and relative intensity of staining throughout all of 
the specimens. Representative photos were taken of specimens to show characteristic 
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staining patterns for the matrix proteins and angiogenesis factors. It must be stressed that 
the patterns of expression described in the results were consistent throughout all of the 
specimens. No preference was given to particular specimens. Although the impact of 
these artifactual factors can be minimized through consistent protocols and controls as 
instituted in our study, the absolute presence or absence of immunostaining is more reliable 
than the relative degree of staining. 
The above limitations notwithstanding, we have documented gross and abnormal 
expression of angiogenic growth factors in aneurysm walls. The relationship of this 
activity to arterial wall integrity, to perilesional edema, and to lesion growth (in part 
through neovessel invasion) cannot be ascertained at the present time. Similarly, the 
relationship and time course of this angiogenic activity to the structural disruption within 
the aneurysm wall can be inferred, but remains unproven. 
Experimental models of inherited or acquired aneurysmal lesions may allow a systematic 
study of the time course of these documented changes during the course of aneurysm 
formation and growth. (75,76] Several animal models that allow a controlled study of 
aneurysm formation and growth have appeared in the literature. Most involve the 
placement of a venous pouch onto bifurcation points of cerebral or carotid arteries. These 
result in outpouchings that mimic the hemodynamic features of human cerebral 
aneurysms.[77] One model that does not involve surgical manipulation of the cerebral 
artery wall involves ligation of the carotid, induction of hypertension, and administration of 
beta-aminopropionitrile. This model may prove advantageous because aneurysms form 
directly out of the artery wall rather than by the placement of a venous pouch. However, 
the model takes as long as 12 months before aneurysm formation occurs and there is a high 
rate of mortality among the animals.[78] In addition to the documentation of gross 
immunostaining, these studies should allow quantitative assays of VEGF or bFGF receptor 
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density and distribution, mRNA levels for the respective probes, and zymographic assays 
of proteolytic and other enzymatic activity in the aneurysm wall over time.[41,79,80] 
VEGF acts directly on vascular endothelial cells by way of two tyrosine kinase receptors 
known as fit-1 and KDR, that are expressed almost exclusively on vascular endothelium. 
Binding of VEGF with receptors causes an increase cytoplasmic calcium, making 
measurement of subpicomolar concentrations of calcium the most sensitive assay currently 
available for detecting VEGF activity. Basic fibroblast growth factor also exerts its effects 
through tyrosine kinase receptors(flg and bek).[62] The availability of antibody probes 
for specific receptor types will give additional information about the role of angiogenesis 
factors in cerebral aneurysms. In situ hybridization and electrophoresis should allow in 
vivo quantification of different angiogenesis growth factor receptors within the wall and 
adventitia of the aneurysm. Measurement of mRNA within endothelial cells, fibroblast, 
and myocytes would give a functional perspective on angiogenesis factor production. 
Basic fibroblast growth factor mRNA has been found in much higher levels in the brain 
than in other tissues. In injured brain tissue the expression of bFGF has been shown to be 
increased and associated with reactive astrocytes. [62,81] In addition techniques have been 
developed to culture endothelial cells from cerebral arteriovenous malformations and 
cavernous malformations. [82] Such techniques allow isolation and more specific in vivo 
analysis of cell function. However, the lack of healthy endothelium in cerebral aneurysm 
specimens has made application of these techniques quite difficult. 
Further studies of human aneurysm specimens will aim to differentiate the portions of the 
aneurysm wall representing impending risk of rupture (wall thinning) in contrast to those 
portions of the aneurysm wall which may be thick, atherosclerotic, or fibrotic. Obviously, 
the latter may represent a more favorable response protecting from wall rupture, and which 
may be sought through therapeutic manipulation. A better understanding of the molecular 
substrates of these two types of biologic response in the aneurysm wall, and specific 
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mechanisms mediating each type, will be required before such attempts at therapeutic 
modification. 
Finally, a number of ongoing studies in molecular genetics are seeking to uncover specific 
genes or gene products mediating aneurysmal disease. [3,7,83,84] At the present time there 
is little evidence of a specific HLA haplotype, antigen, or biochemical association within 
familial clusters of intracranial aneurysms.[3] Until specific biologic markers are found, 
MRI or angiography is the only way to screen for pathology in asymptomatic individuals 
with two or more affected family members. Pedigree analysis of family members with 
intracranial aneurysms seem to best fit with either an autosomal dominant or autosomal 
recessive pattern. Further study of gene products in diseases such as alpha 1 antitrypsin 
deficiency, Ehlers-Danlos syndrome, hereditary hemorrhagic telangiectasia, Marfans, and 
other connective tissue diseases in which aneurysms occur with increased frequency may 
provide further clues. The identification of mechanisms that mediate aneurysmal disease 
will allow specific investigations aimed at their linkage to the angiogenic cascade. 
Enhancement or inhibition of such gene expression may further modify the process of 
aneurysmal disease. 
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